UniProt ID | TRAF6_HUMAN | |
---|---|---|
UniProt AC | Q9Y4K3 | |
Protein Name | TNF receptor-associated factor 6 | |
Gene Name | TRAF6 | |
Organism | Homo sapiens (Human). | |
Sequence Length | 522 | |
Subcellular Localization | Cytoplasm . Cytoplasm, cell cortex . Nucleus . Lipid droplet . Found in the nuclei of some aggressive B-cell lymphoma cell lines as well as in the nuclei of both resting and activated T- and B-lymphocytes. Found in punctate nuclear body protein compl | |
Protein Description | E3 ubiquitin ligase that, together with UBE2N and UBE2V1, mediates the synthesis of 'Lys-63'-linked-polyubiquitin chains conjugated to proteins, such as IKBKG, IRAK1, AKT1 and AKT2. Also mediates ubiquitination of free/unanchored polyubiquitin chain that leads to MAP3K7 activation. Leads to the activation of NF-kappa-B and JUN. May be essential for the formation of functional osteoclasts. Seems to also play a role in dendritic cells (DCs) maturation and/or activation. Represses c-Myb-mediated transactivation, in B-lymphocytes. Adapter protein that seems to play a role in signal transduction initiated via TNF receptor, IL-1 receptor and IL-17 receptor. Regulates osteoclast differentiation by mediating the activation of adapter protein complex 1 (AP-1) and NF-kappa-B, in response to RANK-L stimulation. Together with MAP3K8, mediates CD40 signals that activate ERK in B-cells and macrophages, and thus may play a role in the regulation of immunoglobulin production.. | |
Protein Sequence | MSLLNCENSCGSSQSESDCCVAMASSCSAVTKDDSVGGTASTGNLSSSFMEEIQGYDVEFDPPLESKYECPICLMALREAVQTPCGHRFCKACIIKSIRDAGHKCPVDNEILLENQLFPDNFAKREILSLMVKCPNEGCLHKMELRHLEDHQAHCEFALMDCPQCQRPFQKFHINIHILKDCPRRQVSCDNCAASMAFEDKEIHDQNCPLANVICEYCNTILIREQMPNHYDLDCPTAPIPCTFSTFGCHEKMQRNHLARHLQENTQSHMRMLAQAVHSLSVIPDSGYISEVRNFQETIHQLEGRLVRQDHQIRELTAKMETQSMYVSELKRTIRTLEDKVAEIEAQQCNGIYIWKIGNFGMHLKCQEEEKPVVIHSPGFYTGKPGYKLCMRLHLQLPTAQRCANYISLFVHTMQGEYDSHLPWPFQGTIRLTILDQSEAPVRQNHEEIMDAKPELLAFQRPTIPRNPKGFGYVTFMHLEALRQRTFIKDDTLLVRCEVSTRFDMGSLRREGFQPRSTDAGV | |
Overview of Protein Modification Sites with Functional and Structural Information | ||
* ASA = Accessible Surface Area
Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
---|---|---|---|---|---|
46 | Phosphorylation | TASTGNLSSSFMEEI CCCCCCCCHHHHHHH | 28.12 | 27690223 | |
47 | Phosphorylation | ASTGNLSSSFMEEIQ CCCCCCCHHHHHHHC | 30.66 | 27690223 | |
48 | Phosphorylation | STGNLSSSFMEEIQG CCCCCCHHHHHHHCC | 25.82 | 27690223 | |
56 | Phosphorylation | FMEEIQGYDVEFDPP HHHHHCCCCCCCCCC | 10.63 | 27690223 | |
104 | Ubiquitination | SIRDAGHKCPVDNEI HHHHCCCCCCCCCHH | 39.04 | 29967540 | |
124 | Ubiquitination | LFPDNFAKREILSLM CCCCCCHHHHHHHHH | 46.56 | 18093978 | |
124 | Sumoylation | LFPDNFAKREILSLM CCCCCCHHHHHHHHH | 46.56 | 17135271 | |
124 | Sumoylation | LFPDNFAKREILSLM CCCCCCHHHHHHHHH | 46.56 | - | |
142 | Sumoylation | PNEGCLHKMELRHLE CCCCCCHHHHHHHHH | 22.56 | - | |
142 | Sumoylation | PNEGCLHKMELRHLE CCCCCCHHHHHHHHH | 22.56 | 18093978 | |
188 | Phosphorylation | DCPRRQVSCDNCAAS CCCCCCCCCCCCHHH | 13.86 | 24247654 | |
217 | Phosphorylation | LANVICEYCNTILIR HHHHHHHHHCCEEEE | 6.13 | 22468782 | |
220 | Phosphorylation | VICEYCNTILIREQM HHHHHHCCEEEECCC | 17.38 | 22468782 | |
266 | Phosphorylation | ARHLQENTQSHMRML HHHHHHHHHHHHHHH | 30.60 | - | |
288 | Phosphorylation | SVIPDSGYISEVRNF CCCCCCCCHHHHHCH | 12.77 | - | |
322 | Phosphorylation | ELTAKMETQSMYVSE HHHHHHHHHHHHHHH | 23.57 | 25907765 | |
324 | Phosphorylation | TAKMETQSMYVSELK HHHHHHHHHHHHHHH | 21.36 | 25907765 | |
326 | Phosphorylation | KMETQSMYVSELKRT HHHHHHHHHHHHHHH | 13.18 | 19658100 | |
328 | Phosphorylation | ETQSMYVSELKRTIR HHHHHHHHHHHHHHH | 21.52 | 25907765 | |
331 | Ubiquitination | SMYVSELKRTIRTLE HHHHHHHHHHHHHHH | 43.36 | 22817900 | |
353 | Phosphorylation | AQQCNGIYIWKIGNF HHHCCCEEEEEECCE | 11.35 | 18083107 | |
365 | Ubiquitination | GNFGMHLKCQEEEKP CCEEEEEEECCCCCC | 21.13 | 29967540 | |
371 | Ubiquitination | LKCQEEEKPVVIHSP EEECCCCCCEEEECC | 46.52 | 29967540 | |
390 | Glutathionylation | GKPGYKLCMRLHLQL CCCHHHHHHHHCCCC | 0.99 | 22833525 | |
438 | Phosphorylation | RLTILDQSEAPVRQN EEEEECCCCCCCCCC | 35.08 | 27732954 | |
453 | Sumoylation | HEEIMDAKPELLAFQ HHHHHHCCHHHHHEE | 34.46 | 18093978 | |
453 | Sumoylation | HEEIMDAKPELLAFQ HHHHHHCCHHHHHEE | 34.46 | - | |
486 | Phosphorylation | LEALRQRTFIKDDTL HHHHHHCCCCCCCEE | 22.75 | - | |
489 | Ubiquitination | LRQRTFIKDDTLLVR HHHCCCCCCCEEEEE | 45.41 | 24816145 | |
492 | Phosphorylation | RTFIKDDTLLVRCEV CCCCCCCEEEEEEEE | 31.93 | - | |
507 | Phosphorylation | STRFDMGSLRREGFQ ECCCCCCCCCCCCCC | 16.44 | 30108239 | |
518 | Phosphorylation | EGFQPRSTDAGV--- CCCCCCCCCCCC--- | 31.02 | 25056879 |
Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
---|---|---|---|---|---|---|
- | K | Ubiquitination | E3 ubiquitin ligase | PELI3 | Q8N2H9 | PMID:23042151 |
- | K | Ubiquitination | E3 ubiquitin ligase | STUB1 | Q9UNE7 | PMID:24578159 |
- | K | Ubiquitination | E3 ubiquitin ligase | TRAF3IP2 | O43734 | PMID:19825828 |
- | K | Ubiquitination | E3 ubiquitin ligase | TRAF6 | Q9Y4K3 | PMID:17135271 |
- | K | Ubiquitination | E3 ubiquitin ligase | TRIM23 | P36406 | PMID:15684077 |
- | K | Ubiquitination | E3 ubiquitin ligase | BIRC2 | Q13490 | PMID:20097753 |
- | K | Ubiquitination | E3 ubiquitin ligase | BIRC3 | Q13489 | PMID:20097753 |
- | K | Ubiquitination | E3 ubiquitin ligase | WWP1 | Q9H0M0 | PMID:23799152 |
- | K | Ubiquitination | E3 ubiquitin ligase | TRIM38 | O00635 | PMID:22323536 |
- | K | Ubiquitination | E3 ubiquitin ligase | PRKN | O60260 | PMID:31558697 |
* Distance = the distance between SAP position and PTM sites.
Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of TRAF6_HUMAN !! |
Kegg Disease | ||||||
---|---|---|---|---|---|---|
There are no disease associations of PTM sites. | ||||||
OMIM Disease | ||||||
There are no disease associations of PTM sites. | ||||||
Kegg Drug | ||||||
There are no disease associations of PTM sites. | ||||||
DrugBank | ||||||
There are no disease associations of PTM sites. |
loading...
Sumoylation | |
Reference | PubMed |
"Nuclear tumor necrosis factor receptor-associated factor 6 inlymphoid cells negatively regulates c-Myb-mediated transactivationthrough small ubiquitin-related modifier-1 modification."; Pham L.V., Zhou H.J., Lin-Lee Y.C., Tamayo A.T., Yoshimura L.C.,Fu L., Darnay B.G., Ford R.J.; J. Biol. Chem. 283:5081-5089(2008). Cited for: SUBCELLULAR LOCATION, FUNCTION, SUMOYLATION AT LYS-124; LYS-142 ANDLYS-453, UBIQUITINATION, INTERACTION WITH HDAC1 AND RANGAP1, ANDMUTAGENESIS OF LYS-124; LYS-142 AND LYS-453. | |
"Site-specific Lys-63-linked tumor necrosis factor receptor-associatedfactor 6 auto-ubiquitination is a critical determinant of I kappa Bkinase activation."; Lamothe B., Besse A., Campos A.D., Webster W.K., Wu H., Darnay B.G.; J. Biol. Chem. 282:4102-4112(2007). Cited for: MUTAGENESIS OF CYS-70 AND LYS-124, UBIQUITINATION AT LYS-124, ANDFUNCTION. |